Dalbavancin

Names

[ Name ]:
Dalbavancin

[Synonym ]:
Dalvance
Zeven
Dalbavancin
(1S,2R,19R,22R,33S,36R,39R,51S)-5,31-Dichloro-51-{[3-(dimethylamino)propyl]carbamoyl}-2,25,30,43,48-pentahydroxy-46-(α-D-mannopyranosyloxy)-22-(methylamino)-21,34,37,53,55,58-hexaoxo-7,13,27-triox a-20,35,38,52,54,57-hexaazaundecacyclo[37.14.2.2.2.2.2.1.1.1.0.0]hexahexaconta-3,5,8(64),9,11,14,16,23,25,28(59),29,31,40(56),41,43,45,47,49 ,60,62,65-henicosaen-64-yl 2-deoxy-2-[(10-me

Biological Activity

[Description]:

Dalbavancin is a lipoglycopeptide antibiotic agent that is active against gram-positive pathogens.

[Related Catalog]:

Research Areas >> Infection

Signaling Pathways >> Anti-infection >> Bacterial

[Target]

MIC90: 0.06 μg/mL (Staphylococcus aureus) and 0.25 μg/mL (Bacillus anthracis)[1][2]

[In Vitro]

Dalbavancin is a parenterally administered semisynthetic lipoglycopeptide developed to combat infections caused by resistant gram-positive pathogens. Dalbavancin exhibits potent in vitro bactericidal activity against gram-positive pathogens including S. aureus (MRSA), VISA, and non-VanA strains of VRE. Dalbavancin is developed for the treatment of complicated skin and skin structure infections (cSSSIs), predominantly those caused by MRSA and β-hemolytic streptococci, organisms against which it has shown greater potency than existing glycopeptide therapeutic agents[1][2].

[In Vivo]

Dalbavancin (15-240 mg/kg; intraperitoneal injection; every 36 h or 72 h; for 14 days; female BALB/c mice) treatment has a survival rate of 80% to 100% of mice with all dose regimens[1]. Animal Model: Female BALB/c mice (6-8 weeks) challenged with Ames strain of B. anthracis[1] Dosage: 15 mg/kg, 30 mg/kg, 60 mg/kg, 120 mg/kg, 240 mg/kg Administration: Intraperitoneal injection; every 36 h or 72 h; for 14 days Result: The efficacy was 80 to 100%, as determined by the rate of survival at 42 days, when treatment was initiated 24 h postchallenge with regimens of 15 to 120 mg/kg every 36 h or 30 to 240 mg/kg every 72 h.

[References]

[1]. Heine HS, et al. Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model. Antimicrob Agents Chemother. 2010 Mar;54(3):991-6.

[2]. Bennett JW, et al. Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review. Ther Clin Risk Manag. 2008 Feb;4(1):31-40.

Chemical & Physical Properties

[ Density]:
1.6±0.1 g/cm3

[ Molecular Formula ]:
C₈₈H₁₀₀Cl₂N₁₀O₂₈

[ Molecular Weight ]:
1816.692

[ Exact Mass ]:
1814.608521

[ PSA ]:
572.51000

[ LogP ]:
2.94

[ Index of Refraction ]:
1.729

[ Storage condition ]:
-20℃

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.